Therapeutic approach with squaric acid dibutylester for steroid resistant-alopecia areata incognita: A pilot study of a single center.
alopecia areata
alopecia areata incognita
squaric acid dibutylester (SADBE)
steroid therapy
trichoscopy
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
07
04
2021
accepted:
05
08
2021
pubmed:
15
8
2021
medline:
3
11
2021
entrez:
14
8
2021
Statut:
ppublish
Résumé
Topical immunotherapy is widely used in the treatment of alopecia areata (AA). Alopecia areata incognita (AAI) is a relatively common disorder, predominantly affecting females, characterized by widespread hair thinning in the absence of typical alopecic patches. AAI can have a chronic relapsing course and in some cases can be resistant to current standard treatments. Topical immunotherapy has been used in the management of AA with encouraging results, but to date there are no literature studies reporting the efficacy of topical immunotherapy with squaric acid dibutylester (SADBE) in AAI. The aim of our study is to evaluate the efficacy and tolerance of topical immunotherapy with SADBE in AAI not responding to conventional steroid therapy. A total of 12 patients were enrolled in our Hair Disease Outpatient Service, with a proved histological diagnosis of AAI, and resistant to classical steroid therapy. Each patient underwent global photography, pull test, and trichoscopy at beginning and during the follow-ups. The efficacy of topical immunotherapy with SADBE was assessed by evaluating the changes of clinical and trichoscopic signs. Complete regrowth was achieved in 66.7% of cases (8/12), three patients remained unchanged on clinical evaluation but showed subclinical improvement on trichoscopy, whereas one patient progressed and worsened both on clinical and trichoscopic examination. All patients reported scalp diffuse mild erythema and itching the day after the application of SADBE, which were well tolerated. Three patients developed reactive cervical lymphoadenomegaly. No other side effects were observed. Topical immunotherapy with SADBE is widely used in the management of patchy AA and can be considered an effective alternative in resistant AAI, providing visible clinical and trichoscopic improvement in the majority of cases. Further studies are warranted to confirm and validate our findings.
Substances chimiques
Cyclobutanes
0
Steroids
0
squaric acid dibutyl ester
4RTO57VG65
squaric acid
SVR9D0VODW
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15096Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Rebora A. Alopecia areata incognita: a hypothesis. Dermatologica. 1987;174:214-218.
Molina L, Donati A, Valente NS, et al. Alopecia areata incognita. Clinics (Sao Paulo). 2011;66(3):513-515.
Alessandrini A, Bruni F, Piraccini BM, Starace M. Common causes of hair loss - clinical manifestations, trichoscopy and therapy. J Eur Acad Dermatol Venereol. 2021;35(3):629-640.
Zerbinati N, Esposito C, D'Este E, Calligaro A, Valsecchi R. Topical immunotherapy of alopecia areata: a large retrospective study. Dermatol Ther (Heidelb). 2018;8(1):101-110. https://doi.org/10.1007/s13555-018-0226-5
Jin P, Ki-Hun S, Kyung-Hwa N. Circumscribed alopecia areata incognita. Australas J Dermatol. 2013;54:52-54.
Alessandrini A, Starace M, Bruni F, et al. Alopecia areata incognita and diffuse alopecia areata: clinical, Trichoscopic, histopathological, and therapeutic features of a 5-year study. Dermatol Pract Concept. 2019;9(4):272-277.
Tosti A, Whiting D, Iorizzo M, et al. The role of scalp dermoscopy in the diagnosis of alopecia areata incognita. J Am Acad Dermatol. 2008;59:64-67.
Miteva M, Misciali C, Fanti PA, Tosti A. Histopathologic features of alopecia areata incognito: a review of 46 cases. J Cutan Pathol. 2012;39(6):596-602.
Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British Association of Dermatologists' guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166:916-926.
Choi Y, Kim DH, Jin SY, Lee AY, Lee SH. Topical immunotherapy with diphenylcyclopropenone is effective and preferred in the treatment of periungual warts. Ann Dermatol. 2013;25(4):434-439.
Dall'oglio F, Nasca MR, Musumeci ML, et al. Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial. J Dermatolog Treat. 2005;16(1):10-14.
Lee S, Kim BJ, Lee YB, Lee WS. Hair regrowth outcomes of contact immunotherapy for patients with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(10):1145-1151.